Stem Cell Transplant and Cellular Therapy - Autologous

**Multiple Myeloma**
- IRB# 17699: A Phase III study for treatment with BL-8040 or placebo and G-CSF for the mobilization of hematopoietic stem cells. Bioline GENESIS

**Mantle Cell Lymphoma**
- IRB# 18600: A Phase 3 study evaluating the safety and efficacy of JCARH125 in subjects with relapsed or refractory Multiple Myeloma. Juno EVOLVE

**Diffuse Large B Cell Lymphoma**
- IRB# 18286: A Phase III study evaluating the effectiveness of Rituximab maintenance therapy. EA4151 MCL

**AML and MDS**
- IRB# 15993: A Phase 2 study evaluating the safety and activity of BPX-701 in patients with relapsed AML and previously treated MDS.

**Non-Hodgkin Lymphoma**
- IRB# 18449: A Phase 3 study to compare JCAR017 versus Standard of Care in patients with Relapsed or Refractory Non-Hodgkin Lymphomas (TRANSFORM)

**CAR-T**
- IRB# 18830: Ibrutinib Before and After Stem Cell Transplant in patients with relapsed or refractory Diffuse Large B-Cell Lymphoma.
- IRB# 18855: A Phase IB, Multicenter Study to Determine the Safety and Tolerability of Tisagenlecleucel in Combination with Ibrutinib in Adult Patients with Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- IRB# 18449: A Phase 2 study to determine the safety and effectiveness of tisagenlecleucel in adult patients with relapsed or refractory follicular lymphoma. (BELINDA)
- IRB# 18967: A Phase 3 study comparing treatment with tisagenlecleucel versus Standard of Care in patients with aggressive B-Cell Non-Hodgkin Lymphoma. (BELINDA)

**Key**
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php